moderna covid - Search News

News

Pfizer, Moderna and BioNTech

Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.

Fast Company · 1d

Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna’s patents at London’s Court of Appeal.

MarketWatch · 1d

Moderna Says U.K. Court Rules in Favor of its EP'949 Patent, Affirms Infringement by Pfizer and BioNTech

Moderna said a court ruled in favor of one of its patents and that it was infringed on by a competing vaccine. The biotechnology company on Friday said the U.K. Court of Appeal upheld the validity of its EP'949 patent.

wacotrib · 1d

UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent.

Moderna cuts 2025 revenue to $2.2B

Reuters on MSN · 1d

Moderna cuts sales forecast on UK revenue delay, shares fall

Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, overshadowing lower-than-expected second-quarter loss and sending its shares down 7%.

Investopedia · 1d

Moderna Stock Drops as Firm Cuts Revenue Outlook on UK Vaccine Deliveries Delay

Shares of Moderna fell sharply Friday after the company lowered the top end of its full-year revenue outlook because of a delay in vaccine deliveries to the UK.

invezz on MSN · 1d

Moderna cuts 2025 revenue to $2.2B after UK booster delay

Moderna has lowered the high end of its 2025 revenue forecast, citing a delay in Covid vaccine shipments to the UK. The company now expects between $1.5 billion and $2.2 billion in revenue, down $300 million at the top of its earlier range.

1don MSN

Moderna quarterly sales beat Street estimates on COVID booster sales, cost cuts

Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...

2don MSN

Moderna to Cut 10% of Staff to Offset Slowing Covid Business

Moderna Inc. is cutting about 10% of its workforce, part of an effort by the struggling biotech company to reduce spending as ...

Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

2don MSN

Moderna will lay off 10% of employees, Massachusetts-based company announces

Massachusetts-based Moderna, one of the companies at the forefront of developing a vaccine during the COVID pandemic, ...

Moderna falls as cost-cutting fails to appease investors

Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the ...

Moderna Announces 10% Workforce Cut Amid Declining COVID-19 Vaccine Sales, Regulatory Hurdles

Moderna Inc. (NASDAQ: MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year ...

9hon MSN

Will health insurance pay for Covid vaccines this fall?

HHS Secretary Robert F. Kennedy Jr. has upended the way Covid vaccines are approved and for whom they’re recommended, ...

2don MSN

Pandemic darlings Moderna, BioNTech are now on two different paths

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

1don MSN

Moderna Logs Sales Beat Despite Declining Vaccine Demand

Moderna’s second-quarter sales fell less sharply than Wall Street expected as it works to expand its offerings amid weakening ...

Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump

Just one day after CEO Stéphane Bancel’s sudden announcement of a 10% workforce reduction, Moderna has released Q2 2025 that ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results